Protective four amino acid epitope against Plasmodium vivax mala

Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 4 to 5 amino acid residues in defined sequence

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

514895, A61K 3700

Patent

active

050950932

ABSTRACT:
A synthetic peptide of the human malaria Plasmodium vivax, containing at st one repeat of a synthetic peptide having the amino acid sequence Ala-Gly-Asp-Arg (AGDR) which is a protective epitope found on the circumsporozoite (CS) protein of the sporozoites of the human maleria Plasmodium vivax. When a monoclonal antibody specific for this four amino acid sequence binds to the CS protein of the P. vivax sporozoite in vivo, infection is prevented. Also described are pharmaceutical formulations of these peptides.

REFERENCES:
patent: 4466917 (1984-08-01), Nussenzweig et al.
patent: 4693994 (1987-09-01), McCutchan et al.
patent: 4707357 (1987-11-01), Dame et al.
patent: 4826957 (1989-05-01), Nussenzweig et al.
patent: 4957869 (1990-09-01), Arnot et al.
Collins et al., Am. J. Trop. Med. Hyg., 40(5), 1989, pp. 455-464.
Fundamental Immunology, William E. Paul, ed., pp. 975-977 (1989).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Protective four amino acid epitope against Plasmodium vivax mala does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protective four amino acid epitope against Plasmodium vivax mala, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protective four amino acid epitope against Plasmodium vivax mala will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2285612

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.